Mortality and economic cost in common primary cancer admitted with COVID-19: Analysis of NIS 2020.

Authors

null

Thanathip Suenghataiphorn

Griffin Hospital, Derby, CT

Thanathip Suenghataiphorn , Phuuwadith Wattanachayakul , Thitiphan Srikulmontri , Narathorn Kulthamrongsri , Nutchapon Xanthavanij , Narisara Tribuddharat , Kochakorn Buasri , Pojsakorn Danpanichkul , Sakditad Saowapa , Tuntanut Lohawatcharagul , Soravis Alm Osataphan

Organizations

Griffin Hospital, Derby, CT, Department of Medicine, Albert Einstein Healthcare Network, Philadelphia, PA, Siriraj Hospital, Bangkok, Thailand, Mayo Clinic, Pheonix, AZ, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, St. Elizabeth's Medical Center, Brighton, MA, Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand, Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, Texas Tech University Health Sciences Center, Lubbock, TX, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, Beth Israel Deaconess Medical Center, Boston, MA

Research Funding

No funding sources reported

Background: Recent data showed the detrimental effects of COVID-19 infection on various conditions, resulting in a wide range of health disparities and worsening outcomes, as well as an increased burden of cost. However, limited information exists on the impacts of COVID-19 infection on the most commonly admitted with primary cancer, regarding clinical and economic impact. Methods: We analyzed the 2020 U.S. National Inpatient Sample (NIS) to investigate the effects of COVID-19 infection on cases primarily admitted with the most common admitted with primary cancer, using relevant ICD-10 CM codes. Adjusted odds ratios (aORs) for specified outcomes were calculated through multivariable logistic and linear regression analyses. The primary outcome was inpatient mortality, with secondary outcomes including the cost of hospitalization and length of stay. Statistical significance was established at a p-value of 0.05. Results: We estimated 919,104 hospitalizations with a primary discharge diagnosis of cancer conditions. Of these, 0.54% (4,985/919,104) had a concurrent diagnosis of COVID-19 infection and 46.1% were female. The mean age was 63.6 years old and Caucasians dominated the majority of the records (69.7%), followed by Hispanics (13.1%). In a multivariable logistic and linear regression model adjusting for patient and hospital factors, COVID-19 infection was associated with higher in-hospital mortality for all cancer conditions and other outcome. The txable denotes all-type and subpopulation analysis. Conclusions: In conclusion, our study encompasses all most common admitted primary cancer conditions and shed light how COVID-19 infection is associated with higher in-hospital mortality, prolonged hospital stays, and increased economic burden in various condition. Future longitudinal studies are warranted to comprehensively assess the long-term health sequelae in this population.

Adjusted odd ratios and beta-coefficient for each outcome, stratified by subpopulation groups.

ConditionsEstimated HospitalizationMortalityLength of Stay**ChargesCosts
Lower Colon Cancer116,6056.50 (3.60, 11.73)*4.75 (2.51, 6.99)*41,561 (3,044, 80,078)*6,634 (589, 12,680)*
Lung and Bronchus Cancer103,3345.39 (3.01, 9.64)*5.51 (2.59, 8.43)*37,389 (-9,847, 84,626)10,683 (784, 20,581)*
Leukemia43,9962.87 (1.61, 5.10)*2.34 (-1.99, 6.67)2,561 (-103,233, 108,356)6,925 (-27,997, 41,849)
Lymphoma39,9763.01 (1.45, 6.24)*3.28 (-0.10, 6.66)22,660 (-51,201, 96,522)306 (-13,841, 14,453)
Kidney Cancer39,849N/A4.89 (0.62, 9.17)*2,953 (-25,437, 31,344)547 (-5,418, 6,513)
Total919,1043.86 (3.15, 4.72)*5.96 (4.93, 6.98)*52,443 (34,209, 70,677)13,907 (9,015, 18,800)

N/A denotes no deaths in subpopulation group, *denotes significant level at p < 0.05, **denotes beta-coefficient.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2024 ASCO Breakthrough

Session Type

Poster Session

Session Title

Poster Session A

Track

Gastrointestinal Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Quality of Care,Healthcare Equity and Access to Care,Population Health,Viral-Mediated Malignancies

Sub Track

Real World Evidence/Real World Data

Citation

J Clin Oncol 42, 2024 (suppl 23; abstr 182)

DOI

10.1200/JCO.2024.42.23_suppl.182

Abstract #

182

Poster Bd #

J10

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Annual Meeting

The impact of COVID-19 on national trends of hospitalization and outcomes for acute leukemias.

First Author: Prarthna V. Bhardwaj

Abstract

2024 ASCO Annual Meeting

COVID vs. non-COVID oncology patient cohorts: Demographics and cancer variables.

First Author: Bilja Kurian Sajith

First Author: Prarthna V Bhardwaj

Abstract

2023 ASCO Annual Meeting

Impact of obesity on admissions for COVID-19 with concurrent prostate cancer.

First Author: Renuka Verma